Cybin Launches EMBARK and
Co-Sponsors First Clinical Trial to Treat Frontline Clinicians
Experiencing COVID-Related Burnout and Distress with
Psychedelic-Assisted Psychotherapy
-- EMBARK is a ground-breaking
psychotherapy model that integrates leading clinical approaches to
promote supportive healing with psychedelic medicine --
TORONTO, Canada -- June 8, 2021 -- InvestorsHub NewsWire
-- Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the
"Company"), a biotechnology company focused on
progressing psychedelic therapeutics, today announced that it will
co-sponsor a randomized, placebo-controlled trial of
psychedelic-assisted psychotherapy with psilocybin for frontline
clinicians experiencing COVID-related distress. The study will aim
to treat symptoms of depression, anxiety, burnout and
post-traumatic stress among frontline doctors, nurses and
healthcare professionals.
Cybin has formed a strategic collaboration with the University
of Washington to help sponsor the trial, which will be led by Dr.
Anthony Back. The study will be hosted in Seattle, a city hit hard
with an early coronavirus outbreak.
"There is tremendous potential in a collaboration between the
University of Washington and Cybin to move the field forward, and
this project is an incredibly valuable initial step towards a
productive future," said Dr. Anthony Back, who will serve as
Primary Investigator to the clinical trial.
To support the initiative, Cybin's Chief Clinical Officer, Alex
Belser, PhD and Bill Brennan, PhD (candidate) developed EMBARK. The
development of EMBARK has been guided by leading process evidence
for the clinical efficacy of psychedelic-assisted psychotherapy and
demonstrated theories of therapeutic action to support healing.
EMBARK was designed as a transdiagnostic psychotherapy model that
can be adapted to address a range of clinical indications and
populations.
"Our nation's doctors, nurses and clinicians have been
shouldering the burden of COVID-19 by taking care of the sickest
among us. They're experiencing high levels of anxiety, depression
and burnout. Now it's our turn to help them," said Dr. Alex Belser,
Cybin's Chief Clinical Officer. "We are sponsoring research to see
if psychedelic medicine, when used with EMBARK's supportive
therapy, can help clinicians recover from COVID-related
distress."
Dr. Anthony Back is a recognized leader in the fields of
palliative care and oncology. He is a board-certified physician at
the University of Washington, Founding Co-director of the
University of Washington Center for Excellence in Palliative Care,
and a University of Washington professor of Oncology and Medicine.
He is triple board certified in Hospice and Palliative Medicine,
Medical Oncology and General Internal Medicine. He was the
principal investigator for the National Cancer Institute-funded
Oncotalk interventions, which enabled the founding of the nonprofit
VitalTalk, co-wrote Mastering Communication with Seriously
Ill Patients, produced the first iPhone app for clinician
communication skills, and is a Contemplative Studies Fellow of the
Mind and Life Institute. His clinical and research interests
include patient-physician communication and quality of life in
palliative care. Dr. Back earned his medical degree at Harvard
Medical School.
"For more than a year now, frontline clinicians and healthcare
professionals have made immeasurable sacrifices to protect public
health in their communities. We consider it an honor and our duty
to now help support their own healing processes, post-COVID-19. We
are also delighted and proud to launch EMBARK, a ground-breaking
psychotherapy model aimed at delivering best-practice, supportive
healing in conjunction with psychedelic therapeutics. We look
forward to working with and supporting Dr. Anthony Back on this
important program," said Doug Drysdale, CEO of Cybin. Inc.
About Cybin
Cybin is a leading biotechnology company focused on progressing
psychedelic therapeutics by utilizing proprietary drug discovery
platforms, innovative drug delivery systems, novel formulation
approaches and treatment regimens for psychiatric disorders.
Cautionary Notes and Forward-Looking
Statements
Certain statements in this news release related to the Company are
forward-looking statements and are prospective in nature.
Forward-looking statements are not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as "may", "should", "could", "intend",
"estimate", "plan", "anticipate", "expect", "believe" or
"continue", or the negative thereof or similar variations.
Forward-looking statements in this news release may include
statements regarding enhanced liquidity, the value of additional
capital markets exposure, access to institutional and retail
investors, the Company's new strategic brand messaging campaign,
and psychedelic drug development programs to potentially treat
mental health disorders. There are numerous risks and uncertainties
that could cause actual results and Cybin's plans and objectives to
differ materially from those expressed in the forward-looking
information. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
Cybin makes no medical, treatment or health benefit claims about
Cybin's proposed products. The U.S. Food and Drug Administration,
Health Canada or other similar regulatory authorities have not
evaluated claims regarding psilocybin, psychedelic tryptamine,
tryptamine derivatives or other psychedelic compounds or
nutraceutical products. The efficacy of such products has not been
confirmed by approved research. There is no assurance that the use
of psilocybin, psychedelic tryptamine, tryptamine derivatives or
other psychedelic compounds or nutraceuticals can diagnose, treat,
cure or prevent any disease or condition. Vigorous scientific
research and clinical trials are needed. Cybin has not conducted
clinical trials for the use of its proposed products. Any
references to quality, consistency, efficacy and safety of
potential products do not imply that Cybin verified such in
clinical trials or that Cybin will complete such trials. If Cybin
cannot obtain the approvals or research necessary to commercialize
its business, it may have a material adverse effect on Cybin's
performance and operations.
The NEO Exchange has neither approved nor disapproved the
contents of this news release and is not responsible for the
adequacy and accuracy of the contents herein.
Contacts
Investor Contacts:
Tim Regan/Scott Eckstein
KCSA Strategic Communications
Cybin@kcsa.com
Lisa M. Wilson
In-Site Communications, Inc.
lwilson@insitecony.com
Media Contacts:
John Kanakis
Cybin Inc.
John@cybin.com
Cybin (NEO:CYBN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cybin (NEO:CYBN)
Historical Stock Chart
From Sep 2023 to Sep 2024